Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

High-Definition Analysis of Host Protein Stability during Human Cytomegalovirus Infection Reveals Antiviral Factors and Viral Evasion Mechanisms.

Nightingale K, Lin KM, Ravenhill BJ, Davies C, Nobre L, Fielding CA, Ruckova E, Fletcher-Etherington A, Soday L, Nichols H, Sugrue D, Wang ECY, Moreno P, Umrania Y, Huttlin EL, Antrobus R, Davison AJ, Wilkinson GWG, Stanton RJ, Tomasec P, Weekes MP.

Cell Host Microbe. 2018 Sep 12;24(3):447-460.e11. doi: 10.1016/j.chom.2018.07.011. Epub 2018 Aug 16.

2.

Suppression of costimulation by human cytomegalovirus promotes evasion of cellular immune defenses.

Wang ECY, Pjechova M, Nightingale K, Vlahava VM, Patel M, Ruckova E, Forbes SK, Nobre L, Antrobus R, Roberts D, Fielding CA, Seirafian S, Davies J, Murrell I, Lau B, Wilkie GS, Suárez NM, Stanton RJ, Vojtesek B, Davison A, Lehner PJ, Weekes MP, Wilkinson GWG, Tomasec P.

Proc Natl Acad Sci U S A. 2018 May 8;115(19):4998-5003. doi: 10.1073/pnas.1720950115. Epub 2018 Apr 24.

3.

The pentameric complex drives immunologically covert cell-cell transmission of wild-type human cytomegalovirus.

Murrell I, Bedford C, Ladell K, Miners KL, Price DA, Tomasec P, Wilkinson GWG, Stanton RJ.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6104-6109. doi: 10.1073/pnas.1704809114. Epub 2017 May 22.

4.

Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation.

Fielding CA, Weekes MP, Nobre LV, Ruckova E, Wilkie GS, Paulo JA, Chang C, Suárez NM, Davies JA, Antrobus R, Stanton RJ, Aicheler RJ, Nichols H, Vojtesek B, Trowsdale J, Davison AJ, Gygi SP, Tomasec P, Lehner PJ, Wilkinson GW.

Elife. 2017 Feb 10;6. pii: e22206. doi: 10.7554/eLife.22206.

5.

Genetic Stability of Bacterial Artificial Chromosome-Derived Human Cytomegalovirus during Culture In Vitro.

Murrell I, Wilkie GS, Davison AJ, Statkute E, Fielding CA, Tomasec P, Wilkinson GW, Stanton RJ.

J Virol. 2016 Mar 28;90(8):3929-43. doi: 10.1128/JVI.02858-15. Print 2016 Apr.

6.

[Adenoviral Vectors in Gene Therapy].

Pjechová M, Hernychová L, Tomašec P, Wilkinson GW, Vojtěšek B.

Klin Onkol. 2015;28 Suppl 2:2S75-80. Review. Czech.

PMID:
26374162
7.

Human cytomegalovirus: taking the strain.

Wilkinson GW, Davison AJ, Tomasec P, Fielding CA, Aicheler R, Murrell I, Seirafian S, Wang EC, Weekes M, Lehner PJ, Wilkie GS, Stanton RJ.

Med Microbiol Immunol. 2015 Jun;204(3):273-84. doi: 10.1007/s00430-015-0411-4. Epub 2015 Apr 17. Review.

8.

Plasma membrane profiling defines an expanded class of cell surface proteins selectively targeted for degradation by HCMV US2 in cooperation with UL141.

Hsu JL, van den Boomen DJ, Tomasec P, Weekes MP, Antrobus R, Stanton RJ, Ruckova E, Sugrue D, Wilkie GS, Davison AJ, Wilkinson GW, Lehner PJ.

PLoS Pathog. 2015 Apr 14;11(4):e1004811. doi: 10.1371/journal.ppat.1004811. eCollection 2015 Apr.

9.

HCMV pUL135 remodels the actin cytoskeleton to impair immune recognition of infected cells.

Stanton RJ, Prod'homme V, Purbhoo MA, Moore M, Aicheler RJ, Heinzmann M, Bailer SM, Haas J, Antrobus R, Weekes MP, Lehner PJ, Vojtesek B, Miners KL, Man S, Wilkie GS, Davison AJ, Wang ECY, Tomasec P, Wilkinson GWG.

Cell Host Microbe. 2014 Aug 13;16(2):201-214. doi: 10.1016/j.chom.2014.07.005.

10.

[Ananlysis of phosphoproteins and signalling pathways by quantitative proteomics].

Pjechová M, Hernychova L, Tomašec P, Wilkinson GW, Vojtěšek B.

Klin Onkol. 2014;27 Suppl 1:S116-20. Review. Czech.

PMID:
24945548
11.

Quantitative temporal viromics: an approach to investigate host-pathogen interaction.

Weekes MP, Tomasec P, Huttlin EL, Fielding CA, Nusinow D, Stanton RJ, Wang EC, Aicheler R, Murrell I, Wilkinson GW, Lehner PJ, Gygi SP.

Cell. 2014 Jun 5;157(6):1460-72. doi: 10.1016/j.cell.2014.04.028.

12.

Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation.

Fielding CA, Aicheler R, Stanton RJ, Wang EC, Han S, Seirafian S, Davies J, McSharry BP, Weekes MP, Antrobus PR, Prod'homme V, Blanchet FP, Sugrue D, Cuff S, Roberts D, Davison AJ, Lehner PJ, Wilkinson GW, Tomasec P.

PLoS Pathog. 2014 May 1;10(5):e1004058. doi: 10.1371/journal.ppat.1004058. eCollection 2014 May.

13.

Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.

Holcakova J, Muller P, Tomasec P, Hrstka R, Nekulova M, Krystof V, Strnad M, Wilkinson GW, Vojtesek B.

PLoS One. 2014 Feb 21;9(2):e89228. doi: 10.1371/journal.pone.0089228. eCollection 2014.

14.

Human cytomegalovirus suppresses Fas expression and function.

Seirafian S, Prod'homme V, Sugrue D, Davies J, Fielding C, Tomasec P, Wilkinson GW.

J Gen Virol. 2014 Apr;95(Pt 4):933-9. doi: 10.1099/vir.0.058313-0. Epub 2014 Jan 6.

15.

Impact of sequence variation in the UL128 locus on production of human cytomegalovirus in fibroblast and epithelial cells.

Murrell I, Tomasec P, Wilkie GS, Dargan DJ, Davison AJ, Stanton RJ.

J Virol. 2013 Oct;87(19):10489-500. doi: 10.1128/JVI.01546-13. Epub 2013 Jul 24.

16.

Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses.

Smith W, Tomasec P, Aicheler R, Loewendorf A, Nemčovičová I, Wang EC, Stanton RJ, Macauley M, Norris P, Willen L, Ruckova E, Nomoto A, Schneider P, Hahn G, Zajonc DM, Ware CF, Wilkinson GW, Benedict CA.

Cell Host Microbe. 2013 Mar 13;13(3):324-35. doi: 10.1016/j.chom.2013.02.003.

17.

Human cytomegalovirus UL40 signal peptide regulates cell surface expression of the NK cell ligands HLA-E and gpUL18.

Prod'homme V, Tomasec P, Cunningham C, Lemberg MK, Stanton RJ, McSharry BP, Wang EC, Cuff S, Martoglio B, Davison AJ, Braud VM, Wilkinson GW.

J Immunol. 2012 Mar 15;188(6):2794-804. doi: 10.4049/jimmunol.1102068. Epub 2012 Feb 15.

18.

Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication.

Stanton RJ, Baluchova K, Dargan DJ, Cunningham C, Sheehy O, Seirafian S, McSharry BP, Neale ML, Davies JA, Tomasec P, Davison AJ, Wilkinson GW.

J Clin Invest. 2010 Sep;120(9):3191-208. doi: 10.1172/JCI42955. Epub 2010 Aug 2.

19.

Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture.

Dargan DJ, Douglas E, Cunningham C, Jamieson F, Stanton RJ, Baluchova K, McSharry BP, Tomasec P, Emery VC, Percivalle E, Sarasini A, Gerna G, Wilkinson GW, Davison AJ.

J Gen Virol. 2010 Jun;91(Pt 6):1535-46. doi: 10.1099/vir.0.018994-0.

20.

Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112.

Prod'homme V, Sugrue DM, Stanton RJ, Nomoto A, Davies J, Rickards CR, Cochrane D, Moore M, Wilkinson GW, Tomasec P.

J Gen Virol. 2010 Aug;91(Pt 8):2034-9. doi: 10.1099/vir.0.021931-0. Epub 2010 Apr 21.

21.

The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties.

Holcakova J, Tomasec P, Bugert JJ, Wang EC, Wilkinson GW, Hrstka R, Krystof V, Strnad M, Vojtesek B.

Antivir Chem Chemother. 2010 Jan 5;20(3):133-42. doi: 10.3851/IMP1460.

22.

Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function.

Stanton RJ, McSharry BP, Armstrong M, Tomasec P, Wilkinson GW.

Biotechniques. 2008 Dec;45(6):659-62, 664-8.

23.

Proliferation and interleukin 5 production by CD8hi CD57+ T cells.

Chong LK, Aicheler RJ, Llewellyn-Lacey S, Tomasec P, Brennan P, Wang EC.

Eur J Immunol. 2008 Apr;38(4):995-1000. doi: 10.1002/eji.200737687.

24.

Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B.

McSharry BP, Burgert HG, Owen DP, Stanton RJ, Prod'homme V, Sester M, Koebernick K, Groh V, Spies T, Cox S, Little AM, Wang EC, Tomasec P, Wilkinson GW.

J Virol. 2008 May;82(9):4585-94. doi: 10.1128/JVI.02251-07. Epub 2008 Feb 20.

25.

Modulation of natural killer cells by human cytomegalovirus.

Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, Aicheler R, McSharry BP, Rickards CR, Cochrane D, Llewellyn-Lacey S, Wang EC, Griffin CA, Davison AJ.

J Clin Virol. 2008 Mar;41(3):206-12. Review.

26.

Cytomegalovirus destruction of focal adhesions revealed in a high-throughput Western blot analysis of cellular protein expression.

Stanton RJ, McSharry BP, Rickards CR, Wang EC, Tomasec P, Wilkinson GW.

J Virol. 2007 Aug;81(15):7860-72. Epub 2007 May 23.

27.

Adenovirus vector delivery stimulates natural killer cell recognition.

Tomasec P, Wang EC, Groh V, Spies T, McSharry BP, Aicheler RJ, Stanton RJ, Wilkinson GW.

J Gen Virol. 2007 Apr;88(Pt 4):1103-8.

28.

The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1- NK cells.

Prod'homme V, Griffin C, Aicheler RJ, Wang EC, McSharry BP, Rickards CR, Stanton RJ, Borysiewicz LK, López-Botet M, Wilkinson GW, Tomasec P.

J Immunol. 2007 Apr 1;178(7):4473-81.

29.

Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis.

Wills MR, Ashiru O, Reeves MB, Okecha G, Trowsdale J, Tomasec P, Wilkinson GW, Sinclair J, Sissons JG.

J Immunol. 2005 Dec 1;175(11):7457-65.

30.

Characterization of a highly glycosylated form of the human cytomegalovirus HLA class I homologue gpUL18.

Griffin C, Wang EC, McSharry BP, Rickards C, Browne H, Wilkinson GW, Tomasec P.

J Gen Virol. 2005 Nov;86(Pt 11):2999-3008.

31.

Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141.

Tomasec P, Wang EC, Davison AJ, Vojtesek B, Armstrong M, Griffin C, McSharry BP, Morris RJ, Llewellyn-Lacey S, Rickards C, Nomoto A, Sinzger C, Wilkinson GW.

Nat Immunol. 2005 Feb;6(2):181-8. Epub 2005 Jan 9.

32.

The most abundantly transcribed human cytomegalovirus gene (beta 2.7) is non-essential for growth in vitro.

McSharry BP, Tomasec P, Neale ML, Wilkinson GW.

J Gen Virol. 2003 Sep;84(Pt 9):2511-6.

PMID:
12917473
33.

Viral evasion of natural killer cells during human cytomegalovirus infection.

Braud VM, Tomasec P, Wilkinson GW.

Curr Top Microbiol Immunol. 2002;269:117-29. Review.

PMID:
12224505
34.

UL40-mediated NK evasion during productive infection with human cytomegalovirus.

Wang EC, McSharry B, Retiere C, Tomasec P, Williams S, Borysiewicz LK, Braud VM, Wilkinson GW.

Proc Natl Acad Sci U S A. 2002 May 28;99(11):7570-5.

35.

Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40.

Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, Gadola S, Cerundolo V, Borysiewicz LK, McMichael AJ, Wilkinson GW.

Science. 2000 Feb 11;287(5455):1031.

36.
37.

Human cytomegalovirus infection downregulates expression of the cellular aminopeptidases CD10 and CD13.

Phillips AJ, Tomasec P, Wang EC, Wilkinson GW, Borysiewicz LK.

Virology. 1998 Oct 25;250(2):350-8.

38.

Intracellular retention of the corticotrophin-releasing hormone (CRH) precursor within COS-7 cells.

Perone MJ, Windeatt S, Morrison E, Shering A, Tomasec P, Linton E, Lowenstein PR, Castro MG.

J Histochem Cytochem. 1998 Oct;46(10):1193-7.

PMID:
9742076
39.

Use of recombinant herpes simplex virus type 1 vectors for gene transfer into tumour and normal anterior pituitary cells.

Goya RG, Rowe J, Sosa YE, Tomasec P, Lowenstein PR, Castro MG.

Mol Cell Endocrinol. 1998 Apr 30;139(1-2):199-207.

PMID:
9705088
40.
41.

Generation and characterization of an antiserum reactive with a proteolytic processing site within rat procorticotrophin-releasing hormone.

Castro MG, Rowe JM, Murray CA, Tomasec P, Shering AF, Linton EA, Ahmed I, Lowenstein PR.

Neuropeptides. 1995 Oct;29(4):183-92.

PMID:
8584136
42.
43.

Expression of biologically active procorticotrophin-releasing hormone (proCRH) in stably transfected CHO-K1 cells: characterization of nuclear proCRH.

Morrison E, Tomasec P, Linton EA, Lowry PJ, Lowenstein PR, Castro MG.

J Neuroendocrinol. 1995 Apr;7(4):263-72.

PMID:
7647768
45.

Mitogenic effects and nuclear localisation of procorticotrophin-releasing hormone expressed within stably transfected fibroblast cells (CHO-K1).

Castrol MG, Tomasec P, Morrison E, Murray CA, Hodge P, Blanning P, Linton E, Lowry PJ, Lowenstein PR.

Mol Cell Endocrinol. 1995 Jan;107(1):17-27.

PMID:
7796932
46.

Herpes simplex virus 1 (HSV-1) helper co-infection affects the distribution of an amplicon encoded protein in glia.

Lowenstein PR, Fournel S, Bain D, Tomasec P, Clissold P, Castro MG, Epstein AL.

Neuroreport. 1994 Aug 15;5(13):1625-30.

PMID:
7819534
47.

Use of gene transfer to study post-translational modifications of neuropeptides in cell lines.

Tomasec P, Lowenstein PR, Morrison E, Hodge P, Linton EA, Perkins A, Lowry PJ, Castro MG.

Gene Ther. 1994;1 Suppl 1:S64. No abstract available.

PMID:
8542410
48.

Neuropeptide gene transfer into neuronal and glial cell lines.

Castro MG, Hodge P, Corredoira YA, Morrison E, Tomasec P, Murray CA, Lowenstein PR.

Gene Ther. 1994;1 Suppl 1:S15-8.

PMID:
8542384
49.

Nuclear localisation of corticotrophin releasing hormone (CRH) in transfected CHO-K1 cells.

Morrison E, Hodge P, Tomasec P, Lowenstein PR, Linton EA, Lowry PJ, Castro MG.

Biochem Soc Trans. 1993 Aug;21 ( Pt 3)(3):318S. No abstract available.

PMID:
8224463
50.

Intracellular compartmentalisation of procorticotrophin releasing hormone.

Morrison E, Lowenstein PR, Tomasec P, Hodge P, Linton E, Devine J, Lowry PJ, Castro MG.

Biochem Soc Trans. 1993 Feb;21(1):47S. No abstract available.

PMID:
8449331

Supplemental Content

Loading ...
Support Center